Gumintad, Lea Mae P.

HRN: 24-99-46  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/15/2024
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
05/15/2024
05/22/2024
IV
240 Mg
Q6
PCAP Nonsevere
Waiting Final Action 
05/15/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/15/2024
05/15/2024
Q8
65 Mg
IV
T/c Ileus
Waiting Final Action 
05/19/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/19/2024
05/26/2024
IV
600mg
Q6
Hirschsprung Disease; Post-op
Waiting Final Action 
05/25/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/25/2024
06/01/2024
IV
90mg
Q24
PCAP
Waiting Final Action 
07/10/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
07/10/2024
07/17/2024
IV
70mg
Q8
Toxic Megacolon Sec To Hirschsprung’s Disease S/P Diverting Colostomy (05-18-23)
Waiting Final Action 
07/10/2024
CEFUROXIME 750MG (VIAL)
07/10/2024
07/17/2024
IV
120mg
Q8
Toxic Megacolon Sec To Hirschsprung’s Disease S/P Diverting Colostomy (05-18-23)
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: